Figure 3.
Kaplan-Meier curves showing effect of DNMT3A VAF in normal karyotype patients receiving induction chemotherapy in selected genetically defined subpopulations. Effect of high DNMT3A VAF on EFS in cases with (A) NPM1WT/FLT3-ITDWT (8.3 months, n = 8 vs 56.8 months, n = 15; P = .0028), (B) NPM1MUT or FLT3-ITDMUT (14.7 months, n = 19 vs 32.4 months, n = 20; P = .2674), and (C) NPM1MUT/FLT3-ITDMUT (5.5 months, n = 6 vs not reached, n = 8; P = .3444) subpopulations. Values were generated using the log-rank test.